high-specific-activity iodine-131 metaiodobenzylguanidine (HSA-MIBG) 1, which is now marketed as AZEDRA® by Progenics Pharmaceuticals. The first iteration of MIBG was developed in 1979 ...

In most cases, this is the most important safety issue. Once excretion is effectively complete, the external radiation will decline only with the effective half-life, which for iodine-131 is about 8 ...

Radionuclide therapy is changing dynamically. Monoclonal antibody therapies for non-Hodgkins lymphoma using iodine-131; or imaging with indium-111, followed with yttrium-90 for the therapy are the ...

MIBG has been widely used in radiolabelled forms (usually with iodine-131) since the early 1980s for the imaging and treatment of neuroendocrine tumours such as PPGL 3. After I-131 MIBG binds to ...